Online inquiry

IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6197MR)

This product GTTS-WQ6197MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Solid tumors, Adenocarcinoma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ6197MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10268MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LFG 316
GTTS-WQ4977MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA c2G4-N
GTTS-WQ13281MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-06252616
GTTS-WQ2389MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 110
GTTS-WQ1533MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACE-031
GTTS-WQ1769MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ3008MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Angiocept
GTTS-WQ13588MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA QAX-576
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW